Skip to main content
MedPathMedPath Home
Clinical Trials/NCT03087474
NCT03087474
Completed
Not Applicable

Treatment of Venous Thromboembolism in Real-Life Patients: A Nationwide, Population-Based Study

Bristol-Myers Squibb0 sites89,383 target enrollmentDecember 4, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsVenous Thromboembolism

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Venous Thromboembolism
Sponsor
Bristol-Myers Squibb
Enrollment
89383
Primary Endpoint
VTE hospitalization rate in VKA patients by sex
Status
Completed
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

In a population of patients with venous thromboembolism and treated with oral anticoagulants (OAC) in routine clinical practice in Denmark this study will describe patients treated with each OAC

Registry
clinicaltrials.gov
Start Date
December 4, 2015
End Date
June 28, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •All patients ≥ 18 years diagnosed with incident VTE at Danish public hospitals from 2006 through 2015
  • •First-time (index) VTE will be defined as an in- or out-patient diagnosis of DVT or PE among patients redeeming a prescription for anticoagulant drugs within 30 days after index date

Exclusion Criteria

  • •In the analyses on type and duration of anticoagulant use, Patients with cancer will be excluded as they typically receive low molecular heparin directly from the hospital and their use of anticoagulants can therefore not be captured by redeemed prescriptions at pharmacies.

Outcomes

Primary Outcomes

VTE hospitalization rate in VKA patients by sex

Time Frame: Approximately 180 months

VTE hospitalization rate in VKA patients by age

Time Frame: Approximately 180 months

VTE hospitalization rate in NOAC patients by age

Time Frame: Approximately 180 months

Duration of Treatment in NOAC patients

Time Frame: Approximately 180 months

Hospitalization rate in VKA patients for VTE

Time Frame: Approximately 180 months

Hospitalization rate for first-time Venous thromboembolism (VTE) in Vitamin K antagonist (VKA) patients

Hospitalization rate in NOAC patients for VTE

Time Frame: Approximately 180 months

Hospitalization rate for first-time venous thromboembolism in nonvitamin K antagonist oral anticoagulants (NOAC) patients

VTE hospitalization rate in NOAC patients by sex

Time Frame: Approximately 180 months

Duration of treatment in VKA patients

Time Frame: Approximately 180 months

Similar Trials

Completed
Phase 3
Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.Pulmonary Embolism
NCT00740883University Hospital, Brest374
Recruiting
Not Applicable
Prospective study of venous thromboembolism and bleeding complications associated with primary and secondary VTE prevention during pregnancy and postpartum in women with previous VTE, hereditary thrombophilia or antiphospholipid syndromeO22.3D68.5Deep phlebothrombosis in pregnancyPrimary thrombophilia
DRKS00028688niversitätsklinikum RegensburgUniversitäres Gefäßzentrum - Bereich Angiologie1,000
Unknown
Not Applicable
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score MatchingThrombosisDeep Vein ThrombosisSurgery--Complications
NCT03483181Hanoi Medical University4,000
No Longer Available
Not Applicable
Rivaroxaban in Mechanical Valves: RMV StudyProsthesis; Cardiac, Heart, Functional Disturbance as Result
NCT02894307Hospital Ana Nery
Completed
Not Applicable
Contemporary Management And Outcomes In Patients With Venous Thromboembolism RegistryVenous Thromboembolism (Pulmonary embolism and Deep vein thrombosis)
JPRN-UMIN000021132Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University3,000